Lineage Cell Therapeutics Stock (AMEX: LCTX) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 151.00 / 586.31K |
Day Range | - - - |
52 Wk Range | 0.77 - 1.61 |
Market Cap | $177.51M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | AMEX |
RSI | 56 |
Short Interest | 10.81% |
Days to Cover | 44.23 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Lineage Cell Therapeutics (AMEX:LCTX) through any online brokerage.
Other companies in Lineage Cell Therapeutics’s space includes: Macrogenics (NASDAQ:MGNX), Outlook Therapeutics (NASDAQ:OTLK), Innate Pharma (NASDAQ:IPHA), Galectin Therapeutics (NASDAQ:GALT) and Adverum Biotechnologies (NASDAQ:ADVM).
Lineage Cell Therapeutics has a consensus price target of $5.50.
The stock price for Lineage Cell Therapeutics (AMEX: LCTX) is $0.95 last updated September 23, 2024 at 7:00 AM EDT.
There are no upcoming dividends for Lineage Cell Therapeutics.
Lineage Cell Therapeutics’s Q3 earnings are confirmed for Thursday, November 7, 2024.
There is no upcoming split for Lineage Cell Therapeutics.
Lineage Cell Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.